Dr Michael Christie
Research Fellow in Molecular Pathology
Department of Clinical Pathology
219 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis
DOI: 10.1016/j.ebiom.2026.1063892026
Journal article
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps1-10-072026
Journal article
TNF-⍺-mediated myeloid-instructed CD14 CD4 T cells are associated with poor survival in lung adenocarcinoma
DOI: 10.1016/j.xcrm.2026.1025932026
Journal article
Exploratory Economic Evaluation of a Genome Precision Report in Kidney and Liver Transplantation Care
DOI: 10.1016/j.jval.2026.06.0132026
Journal article
Differences in mRNA expression of neuroinflammation-related genes in the temporal lobe of patients with drug-resistant focal epilepsy
DOI: 10.1002/epd2.702202025
Journal article
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors
DOI: 10.1186/s13073-025-01534-52020
Research grants (ARC, NHMRC, MRFF)
Evaluation of a Community-Led Nutrition and Lifestyle Program for Weight Loss and Metabolic Health: A Randomised Controlled Trial.
RECENT SCHOLARLY WORKS
2025
Journal article
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.CCR-25-14492025
Other
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181832025
Other
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182042025
Other
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618201